Compare JAGU & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JAGU | EQ |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.2M | 64.5M |
| IPO Year | N/A | 2018 |
| Metric | JAGU | EQ |
|---|---|---|
| Price | $1.83 | $2.01 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | ★ 424.0K | 324.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.89 |
| 52 Week Low | $2.25 | $0.29 |
| 52 Week High | $3.60 | $2.35 |
| Indicator | JAGU | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 29.58 | 63.27 |
| Support Level | N/A | $1.38 |
| Resistance Level | $3.49 | $1.97 |
| Average True Range (ATR) | 0.46 | 0.18 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 0.14 | 78.02 |
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.